NCT04849390已完成2 期
A Randomized, Placebo-controlled, Double-blind Trial Evaluating the Efficacy, Tolerability and Safety of ESO-101 in Adult Patients With Active Eosinophilic Esophagitis
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- EsoCap AG
- 入组人数
- 43
- 试验地点
- 17
- 主要终点
- Absolute change in peak eosinophil count from Baseline to end of treatment
研究概览
简要总结
This is a randomized, placebo-controlled, double-blind trial to evaluate the efficacy, tolerability, and safety of ESO-101 in adult patients with active eosinophilic esophagitis (EoE). Patients will be screened at 2 visits (Visit 1 and Visit 2) during which their eligibility will be assessed based on endoscopy-independent criteria (Visit 1) and based on the histologic assessment of esophageal biopsy samples taken during the screening endoscopy (Visit 2). Eligible patients will be randomized 2:1 to once-daily treatment with ESO-101 or placebo and treated for 28 days starting on Day 0. Further clinic visits will be performed at Day 14 (Visit 4) and Day 28 (Visit 5, end of treatment) to assess the efficacy, tolerability, and safety. In addition, a safety follow-up call will be scheduled 2 weeks after the end of treatment (Day 42, Visit 6).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
盲法说明
The placebo will be identical to the test product in terms of appearance, constitution of inactive ingredients, packaging, labeling and administration.
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult patients aged 18-70 years;
- •Confirmed clinicopathological diagnosis of EoE (eosinophilic esophagitis);
- •Active and symptomatic EoE, defined as:
- •peak eosinophil count ≥15 eosinophils/high-powered field (hpf) at 2 levels of the esophagus at the screening endoscopy (Visit 2) as measured in a total of 6 hpfs derived from 6 biopsies, 2 each from the proximal, mid, and distal segment of the esophagus;
- •either a dysphagia or odynophagia severity sore of ≥4 on a 11-point numeric rating scale for ≥1 day during the 7 days before Screening (Visit 1);
- •Written informed consent;
- •Willingness and ability to comply with the protocol for the duration of the trial;
- •Negative pregnancy test at Screening (Visit 1) and Day 0 (Visit 3) in women of childbearing potential (i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilization methods include hysterectomy, bilateral salpingectomy, and bilateral oophorectomy);
- •Women of childbearing potential must be willing to use (for a least 3 monthly cycles before the screening endoscopy [Visit 2] and until 4 weeks after the last intake of IMP) a highly effective method of contraception or birth control (failure rate less than 1% per year when used consistently and correctly). Reliable methods for this trial are:
- •combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal);
- •progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable);
- •intrauterine device or intrauterine hormone-releasing system;
- •bilateral tubal occlusion;
- •a vasectomized sexual partner;
- •sexual abstinence (only accepted as true abstinence when this is in line with the preferred and usual lifestyle of the patient; periodic abstinence [e.g. calendar, ovulation, symptothermal, post-ovulation methods, and withdrawal] is not an acceptable method of contraception).
排除标准
- •Women who are pregnant, lactating, possibly pregnant or planning a pregnancy during the trial period;
- •Current or past (within the last 3 months) alcohol or drug abuse;
- •Initiation of a diet-modifying food restriction within 4 weeks before the screening endoscopy (Visit 2) until EOT (end of treatment);
- •Use of systemic corticosteroids or biologic immunomodulators within 3 months before the screening endoscopy (Visit 2) until the EOT;
- •History of non-response to treatment of EoE with topical corticosteroid drugs (defined as no improvement of clinical symptoms of EoE after a minimum of 4 weeks corticosteroid therapy used at appropriate doses according to the investigator's judgment) or requirement of cessation of corticosteroid therapy for EoE treatment due to oral candidiasis or systemic corticosteroid side effects;
- •Use of corticosteroids for treatment of EoE within 4 weeks before the screening endoscopy (Visit 2) until the EOT;
- •Use of inhalable (pulmonary or nasal) corticosteroids within 4 weeks before the screening endoscopy (Visit 2) until the EOT;
- •Asthma requiring corticosteroid therapy in the seasonal allergy period according to the investigator's judgment based on anamnesis until the EOT;
- •Change in proton pump inhibitor (PPI) dosing regimen within 4 weeks before the screening endoscopy (Visit 2) until the EOT;
- •Use of systemic leukotriene receptor antagonists, immunosuppressant therapy, or chronic oral or systemic anticoagulants (such as coumarin derivates, novel oral and subcutaneous anticoagulants) within 2 weeks before Screening (Visit 1) until the EOT;
- •Unable to swallow a test tablet of about the size of the IMP capsule used in the trial;
- •History of diabetes mellitus;
- •Other severe comorbid condition, concurrent medication, or other issue that renders the patient unsuitable to participate in the trial in the judgment of the investigator, including but not limited to: comorbid condition with an estimated life expectancy of ≤12 months, dialysis, severe pulmonary (requiring home oxygen, uncontrolled chronic obstructive pulmonary disease Gold III/IV) or cardiovascular conditions (heart failure New York Heart Association III and IV, uncontrolled hypertension systolic blood pressure by repeated measurement >180mmHg);
- •History of cancer (except non-melanoma skin cancer, or carcinoma in situ of cervix) or treatment with anticancer therapy (chemotherapy, immunotherapy, radiotherapy, hormone therapy for cancer treatment, targeted therapy or gene therapy) within 12 months before Screening (Visit 1) until the EOT;
- •Known intolerability or hypersensitivity to mometasone furoate or any of the IMP excipients (e.g. bovine gelatin, polyvinyl alcohol, polyvinyl acetate, glycerol, sorbitol);
- •Systemic autoimmune disorders or any condition requiring immunosuppression (e.g. methotrexate, cyclosporine, interferon alpha, tumor necrosis factor alpha inhibitors, antibodies to immunoglobulin E) within 3 months before Screening (Visit 1);
- •Mental condition rendering the patient unable to understand the nature, scope, and possible consequences of the trial or presence of any condition that impacts compliance with the trial procedures;
- •Use of any investigational or non-registered product (medicinal product or medical device) within 4 weeks before the screening endoscopy (Visit 2) until the EOT;
- •Employee at the trial center, spouse, partner or child of investigators or sub-investigators or employee of the sponsor.
- •History of or active eosinophilic gastroenteritis and colitis, inflammatory bowel disease, celiac disease, oral or esophageal mucosal infection of any kind, and esophageal varices;
- •Gastroesophageal reflux disease with Los Angeles Grade B or higher, or erosive esophagitis Grade 2 or above;
- •Presence of Barrett's esophagus with a maximum length of ≥3 cm with intestinal metaplasia or dysplasia, peptic stricture, achalasia, significant hiatal hernia >3 cm, esophageal scleroderma, or diagnosis of Lichen planus;
- •Emergency endoscopy for bolus impaction within 2 weeks before Screening (Visit 1);
- •Any mouth or dental condition that prevents normal eating;
- •History of (dilation within the previous 8 weeks) or current severe endoscopic structural abnormality in esophagus (e.g. high-grade stenosis where an 8-10 mm endoscope cannot pass without dilatation at the screening endoscopy [Visit 2]);
- •Diagnosed liver cirrhosis or portal hypertension;
- •History of upper gastrointestinal bleeding within 8 weeks before Screening (Visit 1);
- •Known allergy to β-lactoglobulin (cow milk protein).
研究组 & 干预措施
ESO-101
Experimental
Oral use of 1 hard gelatin capsule (800 μg)
干预措施: ESO-101 (Drug)
Placebo
Placebo Comparator
Oral use of 1 hard gelatin capsule
干预措施: Placebo (Drug)
结局指标
主要结局
Absolute change in peak eosinophil count from Baseline to end of treatment
时间窗: From Baseline (Visit 2) to end of treatment (Visit 5 = 4-7 weeks after Visit 2)
The processing and analysis of biopsy samples taken at Visit 2 and end of treatment (Visit 5) will be performed blinded at a central laboratory according to a laboratory manual. At both visits, 6 biopsy samples will be taken, 2 each from the proximal, mid, and distal segment of the esophagus. Histology results of the biopsies at Visit 2 will be considered baseline values. For the peak number of eosinophils, hematoxylin and eosin stained esophageal biopsy specimen will be assessed and the high-powered fields with the highest density of eosinophils will be counted.
次要结局
- Proportion of patients with a relative reduction in peak eosinophil count of ≥50 percent from Baseline to end of treatment(From Baseline (Visit 2) to end of treatment (Visit 5 = 4-7 weeks after Visit 2))
- Proportion of patients with histological remission, defined as the reduction of peak eosinophil count in all esophageal samples to <15 eosinophils/hpf at end of treatment, overall and determined differentially in each of the 3 esophageal segments(From Baseline (Visit 2) to end of treatment (Visit 5 = 4-7 weeks after Visit 2))
- Proportion of patients with a relative reduction in peak eosinophil count of ≥30 percent from Baseline to end of treatment(From Baseline (Visit 2) to end of treatment (Visit 5 = 4-7 weeks after Visit 2))
- Incidence of treatment-emergent Adverse Events(Visit 3 (Day 0) to day 42)
- Incidence of treatment-emergent Serious Adverse Events(Visit 3 (Day 0) to day 42)
- Absolute change in dysphagia and odynophagia severity scores from Baseline(From Baseline (Visit 3) to end of treatment (Visit 5 = 28 days after Visit 3))
- Relative change in dysphagia and odynophagia severity scores from Baseline(From Baseline (Visit 3) to end of treatment (Visit 5 = 28 days after Visit 3))
- Patient-reported treatment satisfaction at end of treatment based on questions about handling, taste, and time necessary for administration(At end of treatment (Visit 5 = day 28))
- Absolute change in mean eosinophil count from Baseline to end of treatment(From Baseline (Visit 2) to end of treatment (Visit 5 = 4-7 weeks after Visit 2))
- Proportion of patients with histological remission AND improvement in the dysphagia severity score from Baseline to end of treatment(From Baseline (Visit 2 + 3) to end of treatment (Visit 5 = 4-7 weeks after Visit 2))
- Incidence of AESI(Visit 2 (day -21 to -1) to Visit 6 (day 42))
- Proportion of patients with a peak eosinophil count in all esophageal samples of <6 eosinophils/hpf at end of treatment, overall and determined differentially in each of the 3 esophageal segments(End of treatment (Visit 5 = day 28))
- Proportion of patients with an improvement in the dysphagia severity score from Baseline to end of treatment(From Baseline (Visit 3) to end of treatment (Visit 5 = 28 days after Visit 3))
- Relative change in mean eosinophil count from Baseline to end of treatment(From Baseline (Visit 2) to end of treatment (Visit 5 = 4-7 weeks after Visit 2))
- Proportion of patients with a relative reduction in peak eosinophil count of ≥75 percent from Baseline to end of treatment(From Baseline (Visit 2) to end of treatment (Visit 5 = 4-7 weeks after Visit 2))
- Time to achieve symptom relief (defined as 50 percent improvement in the dysphagia or odynophagia symptoms on an NRS compared to Baseline)(From Baseline (Visit 3) to end of treatment (Visit 5 = 28 days after Visit 3))
- Change in the EREFS from Baseline to end of treatment(From Baseline (Visit 2) to end of treatment (Visit 5 = 4-7 weeks after Visit 2))
- Local tolerability(From Baseline (Visit 3) to end of treatment (Visit 5 = 28 days after Visit 3))
研究者
研究点 (17)
Loading locations...
相似试验
招募中
3 期
Evaluate the Efficacy and Safety of Goofice® (Elobixibat) in Patients With Chronic ConstipationConstipationNCT05895877Synmosa Biopharma Corp.351
已完成
1 期
Single-dose Study to Evaluate Safety, Tolerability, and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes MellitusDiabetesType 1 Diabetes MellitusNCT02715193REMD Biotherapeutics, Inc.21
进行中（未招募）
2 期
Study of CM313 (SC) Injection in Subjects With Primary Immune Thrombocytopenia (ITP)Primary Immune ThrombocytopeniaNCT06594146Keymed Biosciences Co.Ltd62
Unknown
不适用
Efficacy and Safety of MK-0518 in Treatment-Experienced HIV-1 Infected Adult Patients With HemophiliaHIV InfectionHemophilia ANCT00797381Shanghai Public Health Clinical Center100
已完成
2 期
A Dose-Response Safety Study of ENX-102 in Patients With GADNCT06653296Engrail Therapeutics INC38